- Home
- LLY vs GILD Comparison
LLY vs GILD Comparison
Compare LLY & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LLY | GILD |
|---|---|---|
| Founded | 1876 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 950.7B | 187.5B |
| IPO Year | 2007 | 2000 |
Fundamental Metrics
Financial Performance| Metric | LLY | GILD |
|---|---|---|
| Price | $1,004.95 | $145.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 19 | 18 |
| Target Price | ★ $1,174.53 | $143.50 |
| AVG Volume (30 Days) | 2.6M | ★ 6.3M |
| Earning Date | 05-04-2026 | 05-13-2026 |
| Dividend Yield | 0.70% | ★ 2.28% |
| EPS Growth | 95.99 | ★ 1684.21 |
| EPS | ★ 22.95 | 6.78 |
| Revenue | ★ $65,179,000,000.00 | $24,689,000,000.00 |
| Revenue This Year | $27.04 | $4.68 |
| Revenue Next Year | $16.26 | $6.10 |
| P/E Ratio | $42.97 | ★ $21.23 |
| Revenue Growth | ★ 44.70 | 9.98 |
| 52 Week Low | $623.78 | $95.30 |
| 52 Week High | $1,133.95 | $157.29 |
Technical Indicators
Market Signals| Indicator | LLY | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 45.69 | 50.89 |
| Support Level | $994.42 | $143.09 |
| Resistance Level | $1,102.49 | $157.29 |
| Average True Range (ATR) | 26.48 | 3.27 |
| MACD | -3.52 | -1.43 |
| Stochastic Oscillator | 39.81 | 24.02 |
Price Performance
Historical ComparisonAbout LLY Eli Lilly and Company
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).